Optimized tools and timing of response reassessment after neoadjuvant chemoradiation in rectal cancer

Junbing Chen1 · Zhouqiao Wu1 · Xiaoyan Zhang2 · Zining Liu3 · Yiding Wang1 · Fei Shan1 · Yinkui Wang1 · Shaojun Xia2 · Yan Zhang1 · Yingshi Sun2 · Jiafu Ji1 · Ziyu Li1

Accepted: 8 October 2022 / Published online: 15 October 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

Abstract

Purpose Reassessment tools of response to long-course neoadjuvant chemoradiation treatment (nCRT) in patients with locally advanced rectal cancer (LARC) are important in predicting complete response (CR) and thus deciding whether a wait-and-watch strategy can be implemented in these patients. Choosing which routine reassessment tools are optimal and when to use them is still unclear and will be researched in the study.

Methods Altogether, 250 patients with LARC who received nCRT from 2013 to 2021 and were followed up were retrospectively reviewed. Common reassessment tools of response included digital rectal examination (DRE), clinical examination and symptoms, endoscopy, biopsy, magnetic resonance imaging (MRI), and blood biomarkers.

Results Overall, 27.20% (68/250) patients had a complete response and 72.80% (182/250) did not. The combination of MRI, endoscopy, and biopsy showed the best performance in terms of accuracy of 74% and area under the curve (AUC, 0.714, 95% CI 0.546–0.882). Reassessing through DRE and presence of symptoms failed to improve the efficacy of response reassessment. After 100 days, biopsy as an assessment tool would obtain a substantial rise in accuracy from 51.28 to 100% (p = 0.003).

Conclusion The combination of MRI, endoscopy, and biopsy is suitable as the reassessment tool of response for applying a wait-and-watch strategy after long-course nCRT in patients with LARC. The accuracy of biopsy as reassessment tools would be improved if they were used over 100 days after nCRT in patients with rectal cancer.

Keywords Rectal cancer · Response reassessment · Wait and watch strategy · Neoadjuvant chemoradiation · Magnetic resonance imaging

Introduction

Rectal cancer accounts for almost half of colorectal cancer cases, which ranks third for incidence, and second for mortality worldwide [1]. A comprehensive treatment is necessary, as the majority of patients are diagnosed with locally advanced rectal cancer (LARC). The multimodal therapies for patients with LARC includes neoadjuvant chemoradiation (nCRT) or total neoadjuvant therapy (TNT), total mesorectal excision (TME), and adjuvant chemotherapy (AC) [2–4]. With the improvement and standardization of multimodal treatment, approximately 15–27% of patients who receive nCRT and TME achieve a pathological complete response (pCR, ypT0N0) as confirmed with pathological studies, and thus have better long-term survival outcome than not pathological complete response (non-pCR) patients [5–7].
Considering the high rate of pCR, the strategy of “wait and watch” was proposed for patients with rectal cancer with clinical complete response (cCR, ycT0N0), meaning that patients could receive strict follow-up instead of having a radical surgery at the cost of anus surgery with serious comorbidities [8]. This method has been confirmed to be feasible and beneficial [9–11]. Therefore, receiving nCRT and omitting radical surgery in cCR patients might be a safe option and holds similar prognosis as pCR patients do.

Currently, the reassessment tools of response include clinical examination and symptoms, digital rectal examination (DRE), endoscopy, biopsy, magnetic resonance imaging (MRI), transrectal ultrasound (TRUS), positron emission tomography-computed tomography (PET-CT), and carcinoma embryonic antigen (CEA). MRI reassessment mainly refers to T2-weighted imaging (T2WI), diffusion weighted imaging (DWI), and dynamic contrast enhancing (DCE). DRE, endoscopy, and MRI have been the main reassessment tools to evaluate the response for implementing the wait-and-watch strategy [12]. However, the independent and integrated value of reassessment tools to predict pCR was undervalued or overvalued [12]. The combination of reassessment tools for pCR prediction is lacking in prospective or even retrospective studies, and there is no consensus about it worldwide. Although nowadays there are various state-of-the-art tools attempting to predict pCR, increasingly promoting the wait-and-watch strategy, such as ctDNA, circulating tumor cells (CTC), exosome or biopitic ncRNA, and intelligent models, most of them are still being studied and none of them was clinical routine due to unsatisfied predicting accuracy or great expenditure [13]. It has been reported in many studies that an extended time interval to surgery by 9–12 weeks or even longer could ensure a better pCR rate or survival outcomes [14–17]. However, whether the timing of response reassessment tools use after nCRT needs to be readjusted to attain a higher predictive accuracy is still uncertain. Therefore, in this study, we attempt to evaluate and compare the value of common reassessment tools of response for a wait-and-watch strategy in patients with rectal cancer, in addition to revealing the influence of time fluctuation on the efficacy of response of the applied reassessment tools. To our knowledge, this is the first study that focuses on the tools and timing of reassessment for a wait-and-watch strategy in rectal cancer.

**Patients and methods**

**Patient selection**

A total of 364 patients were diagnosed with LARC from January 2013, to December 2021, at the Peking University Cancer Hospital and Institute. Ethics approval was granted by the Peking University Cancer Hospital Ethics Committee. The inclusion criteria were as follows: (1) endoscopic biopsy confirmed pathologically locally advanced rectal adenocarcinoma prior to multimodal therapy use; (2) patients received long-course nCRT (without induction or consolidative chemotherapy) followed by response reassessment, then had either surgery or a wait-and-watch strategy. The exclusion criteria were as follows (1) patients with distant metastasis or other diagnosed tumors; (2) patients received multimodal therapy outside our center; (3) absence of baseline information. A total of 250 patients were eligible for further analysis, and their baseline characteristics are shown in Table 1. The study workflow is shown in Fig. 1.

**Multimodal therapy**

Multimodal therapy procedures were discussed through multidisciplinary team cooperation and performed by a stationary oncological team. The 7th edition of the American Joint Committee on Cancer TNM system was used for tumor staging. The long-course of 22-fraction intensity-modulated radiation therapy (IMRT) regimen with concurrent capecitabine at a dose of 825 mg/m² orally twice per day was performed [18], with a total dose of 50.6-Gy gross tumor volume (GTV) and 41.8-Gy clinical target volume (CTV) administered 5 times per week for 30 days [19, 20]. The induction or consolidative chemotherapy was not used in this study group. Following the nCRT, implementation of a wait-and-watch strategy was based on the result of a cCR or near-cCR established through the reassessment tools of response. A non-cCR would lead to radical surgery. Patients who had no residual tumor cells in pathological tissue were considered pCR. It were also considered pCR analogue for analysis who had no sign of relapse within the first two years for wait-and-watch populations [21].

**Response reassessment**

Reassessment tools of response were applied, including clinical examination and symptoms inquiry, DRE, endoscopy, endoscopic biopsy, MRI, PET-CT, and laboratory assays including AFP, CEA, CA199, CA72.4, CA242, CA125, NSE. The tools for evaluation were planned when the nCRT was ended based on multi-disciplinary treatment (MDT) discussion. At least three different reassessment tools were applied to reassess patient response to nCRT. In our practice, definition of rectum follows the international Delphi consensus, and it was considered as the upper rectal boundary when the point of the sigmoid take-off was visualized on imaging [22]. The dentate line was considered as the surgical definition of lower rectal boundary. All the patients were diagnosed using endoscopy and pathological confirmation.
from biopsy, and the distance from the to the lower edge of the tumor to anus was measured and used in our analysis.

Based on the reassessment results, specific therapeutic regimen was decided and developed in the MDT meeting. MRI with T2WI, DWI and DCE were performed with a 3.0 T scanner in our center. There were perspective reports with written records including endoscopy, pathology, MRI, examination, which were further verified by specialists and MDT discussions. cCR, near-cCR, or non-cCR had been assigned during the treatment period, and further quantified in this study. The quantified score was introduced to divide the reassessment reports level, based on previous studies by Maas [10, 12], Habr-Gama [23], MSKRS [24], and ESMO [25], in addition to being designed based on our practice and other research [26]. In addition, the ulcer, irregularity and other related abnormality in reassessment tools of endoscopy were considered potentially non-CR instead of near-cCR. “Normal,” “alleviated,” and “unalleviated” symptoms after nCRT were respectively assigned with 0, 1, 2. Similarly, in the reassessment results of the DRE, “the tumor negative,” “nodularity or abnormality,” and “nodularity with blood” were respectively assigned to 0, 1, 2. In general, a variety of intricate results were simplified into three level and quantified with “0,” “1,” “2,” representing “cCR,” “near-cCR or possible non-cCR,” “non-cCR” respectively. The score details are shown in Table 2, and the definition of cCR or near-cCR was determined by following per under the score in Table 3. Time interval to reassessment (TTR) after the end of nCRT was recorded, including time to clinical examination (TTC), time to DRE (TTD), time to endoscopy (TTE), time to biopsy (TTB), time to MRI (TTM), and time to laboratory biomarker assay (TTA). A time interval > 4 weeks was recommended, and the chosen time was mainly influenced by appointments in line. The schematic overview is shown in Fig. 2.

**Follow-up**

The postoperation follow-up was regularly performed every 3 months for 2 years, and every 6 months for the following 3 years. The overall survival (OS) was measured from the time of nCRT start to the endpoint, including local relapse, distant

---

**Table 1 The patients’ demography and pathology complete response**

| Characteristics                        | All patients | pCR (%) | non-pCR (%) | p value |
|----------------------------------------|--------------|---------|-------------|---------|
| Patients Number                        | 250          | 68/250 (27.20) | 182/250 (72.80) |         |
| Age, median [IQR], y                   | 63 [56–69]   | 62 [56–68] | 64 [56–70] | 0.889   |
| BMI, median [IQR], (kg/m2)             | 24.30 [22.48–26.44] | 24.04 [22.15–26.69] | 24.41 [22.49–26.27] | 0.522 |
| nCRT span, median [IQR], day           | 30 [29–34]   | 30 [29–32] | 31 [29–34] | 0.373   |
| TTS, median [IQR], day                 | 96 [71–113]  | 87 [68–107] | 98 [73–118] | 0.186   |
| Gender (%)                             |              |         |             | 0.264   |
| Male                                   | 175/250 (70.00) | 44/175 (25.14) | 131/175 (74.86) |         |
| Female                                 | 75/250 (30.00) | 24/75 (32.00) | 51/75 (68.00) | 0.608   |
| cT                                      |              |         |             | 0.687   |
| cT1-2                                   | 22/250 (8.80) | 7/22 (31.82) | 15/22 (68.18) |         |
| cT3                                     | 174/250 (69.60) | 49/174 (28.16) | 125/174 (71.84) |         |
| cT4                                     | 54/250 (21.60) | 12/54 (22.22) | 42/54 (77.78) |         |
| cN                                      |              |         |             | 0.878   |
| cN0                                     | 16/250 (6.40) | 5/16 (31.25) | 11/16 (68.75) |         |
| cN1                                     | 69/250 (27.60) | 21/69 (30.43) | 48/69 (69.57) |         |
| cN2                                     | 165/250 (66.00) | 42/165 (25.45) | 123/165 (74.55) |         |
| ycT (n = 242)                           |              |         |             | < 0.001 |
| ycT0                                    | 23/242 (9.50) | 15/23 (65.22) | 8 (34.78) |         |
| ycT1-2                                  | 44/242 (18.18) | 12/44 (27.27) | 32 (72.72) |         |
| ycT3                                    | 150/242 (61.98) | 34/150 (22.67) | 116/150 (77.33) |         |
| ycT4                                    | 25/242 (10.33) | 3/25 (12.00) | 22/25 (88.00) |         |
| ycN (n = 242)                           |              |         |             | 0.008   |
| ycN0                                    | 90/242 (37.19) | 34/90 (37.78) | 56/90 (62.22) |         |
| ycN1                                    | 85/242 (35.12) | 16/85 (18.82) | 69/85 (81.76) |         |
| ycN2                                    | 67/242 (27.69) | 14/67 (20.90) | 53/67 (79.10) |         |

*pCR* pathological complete response, *non-pCR* not pathological complete response, *nCRT* neoadjuvant chemoradiation treatment, *TTS* time to surgery, *cT* clinical T stage, *cN* clinical N stage, *ycT* clinical post-nCRT T stage, *ycN* clinical post-nCRT N stage
metastasis and death, otherwise censored at the last follow-up visit.

Statistics

Descriptive statistics were performed for demographic data, including medians with interquartile ranges (IQRs) and percentages. The Shapiro–Wilk test and Levene test were used for normality and homogeneity tests. The Student T-test, Mann–Whitney U test, or Kruskal–Wallis test was used as appropriate for continuous variables, and Pearson’s chi-square test for categorical variables. The Kaplan–Meier curves and log-rank tests were performed for analysis of OS. The sensitivity, specificity, true positive (TP), false positive (FP), false negative (FN), true negative (TN), accuracy, Youden index, and the area under curve (AUC) were recorded or calculated. The continuous variable cutoff was based on the median or the upper left corner point in receiver operating curves (ROC). In analyses of tools’ performed timing, ROC cutoff is made to highlight the difference of accuracy at its sides. All tests were two-sided, and \( P < 0.05 \) was considered significant. All statistical analyses and plots were done through R software (Version 4.2.0, R Foundation for Statistical Computing).

Results

Patient demographics

Overall, 250 patients with LARC were eligible for the cohort analysis, including 244 (97.60%) patients who had undergone radical surgery and 6 (2.40%) patients who had a wait-and-watch strategy. The demographic characteristics are shown in Table 1. In the 244 patients with radical surgery, 180 (180/244, 73.78%) were pCR and 64 (64/244, 35.56%) were non-pCR. In the 6 patients with a wait-and-watch strategy, 4 (4/6, 66.67%) were relapse-free in 2 years after consideration of cCR, and 2 patients (2/6, 33.33%) relapsed in 2 years and thus received surgery. The four patients were considered to be equivalent to pCR patients in this study. There were no significant differences in baseline characteristics (age, BMI, nCRT span, time to surgery, gender, cT, cN) between pCR and non-pCR patients. Factors of ycT and ycN had significant impacts on the pCR \( (p < 0.001, p = 0.008, \text{respectively}) \), and the results showed that higher ycT and ycN was associated with a lower likelihood for a pCR. The median TTS was 96 days. The median follow-up was 42 months.
Efficacy of reassessment tools in predicting pCR

The reassessment quantified and simplified score is shown in Table 2, and the accumulative score, which was considered as cCR or near-cCR, is shown in Table 3. The reassessment tools or their combinations’ AUC results are shown in Fig. 3 and Supplementary Fig. 1. In 250 patients, 250 (100.00%) underwent clinical symptoms examination and received a DRE, 241 (96.40%) received an MRI reassessment, 60 (24.00%) received endoscopy, and 50 (20.00%) underwent biopsies. Results showed that reassessment tools such as clinical symptoms and DRE had a quite low accuracy (56.00% and 45.20%, respectively) and AUC (0.476 and 0.490, respectively). Although the MRI through discussion of multidisciplinary team (MDT) had a higher accuracy (75.93%), its AUC (0.423) was still low. All the tumor biomarkers from peripheral blood had quite a low accuracy and AUC. For instance, CEA had an accuracy of 63.60%, an AUC of 0.593, and a Youden index of 0.178. Nevertheless, endoscopy, biopsy, and their combination had relatively high accuracies (85.00%, 62.00%, 62.00%, respectively) and AUCs (0.700, 0.693, 0.714, respectively). Moreover, the combination of MRI and endoscopy or MRI, endoscopy, and biopsy also obtained a high accuracy (79.66% and 74.00%, respectively) and AUC (0.687 and 0.714, respectively), which indicated that biopsy failed to improve performance when added into the reassessment combination with MRI and endoscopy. Likewise, regarding MRI, although it could not improve AUC when added into the combination of endoscopy and biopsy (0.714 and 0.714, respectively), it increased the accuracy from 62.00 to 74.00. However, DRE and clinical symptoms, when combined with other tools, failed to improve the accuracy and AUC, and performed even worse in combinations (Table 3).

Impact of timing on the predictive efficacy of the reassessment tools

Time to reassessment (TTR) after nCRT was recorded and analyzed in Table 4, and included TTC, TTD, TTE, TTB, and TTM, with their distribution shown in Supplementary Fig. 2. The threshold of these indicators was determined by a median cutoff or a ROC cutoff. The results were then divided into two groups based on the time threshold, and the accuracy at threshold’s sides was calculated respectively. The true or false predictions in the divided groups were shown in Fig. 4. For TTC, the time to reassessment of clinical examination, which mainly included symptoms, there was no significant difference to any threshold at any time point, inferring that it is feasible to perform a clinical examination at any time. Similarly, for TTM, time to the reassessment of MRI, accuracy before and after 55 days were respectively 72.57% and 79.07%, with a p-value of 0.239. Therefore, the timing of MRI use would make no difference in reassessment efficacy.

However, there were significant differences in TTD, TTE and TTB. For TTD, time to the reassessment of DRE, the accuracy before and after the median cutoff of 91 days was respectively 72.57% and 79.07%, with a p-value of 0.239. Therefore, the timing of MRI use would make no difference in reassessment efficacy.
Table 3: The performance of complete response prediction in reassessment tools combinations

| Tools combination | No. patients (percent of all, %) | Assignment for cCR or near-cCR | TP (percent of patients, %) | TN (percent of patients, %) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (%) | LRN | LRP | Youden | AUC (95% CI) |
|-------------------|----------------------------------|-------------------------------|-----------------------------|----------------------------|----------------|---------------|---------|---------|-------------|-----|-----|--------|--------------|
| Clinical Symptom  | 250 (100.00)                     | 0                             | 28 (11.20)                  | 112 (44.80)                | 41.18          | 61.54         | 28.57   | 73.68   | 56.00       | 0.960         | 1.070         | 0.027     | 0.476 [0.405–0.548] |
| DRE               | 250 (100.00)                     | 0                             | 37 (14.80)                  | 76 (30.40)                 | 54.41          | 41.76         | 25.87   | 71.03   | 45.20       | 1.090         | 0.930         | -0.038    | 0.490 [0.414–0.560] |
| DRE + Symptom     | 250 (100.00)                     | 0                             | 18 (7.20)                   | 139 (55.60)                | 26.47          | 76.37         | 29.51   | 73.54   | 62.80       | 0.963         | 1.120         | 0.028     | 0.490 [0.414–0.566] |
| Endoscopy         | 60 (24.00)                       | 0 or 1                         | 11 (18.33)                  | 40 (66.67)                 | 78.57          | 86.96         | 64.71   | 93.02   | 85.00       | 0.246         | 6.024         | 0.655     | 0.700 [0.535–0.864] |
| Endoscopy + DRE   | 60 (24.00)                       | 0 or 1                         | 10 (16.67)                  | 26 (43.33)                 | 71.43          | 56.52         | 33.33   | 86.67   | 60.00       | 0.505         | 1.643         | 0.280     | 0.693 [0.538–0.848] |
| Biopsy            | 50 (20.00)                       | 0                             | 11 (22.00)                  | 20 (40.00)                 | 84.62          | 54.05         | 39.29   | 90.91   | 62.00       | 0.285         | 1.842         | 0.387     | 0.693 [0.563–0.824] |
| Endoscopy + Biopsy| 59 (23.60)                       | 0 or 1                         | 10 (16.95)                  | 21 (35.59)                 | 76.92          | 56.76         | 38.46   | 87.50   | 62.00       | 0.407         | 1.779         | 0.337     | 0.552 [0.552–0.876] |
| MRI-MDT           | 241 (96.40)                      | 0                             | 12 (8.71)                   | 171 (70.95)                | 18.75          | 96.61         | 66.67   | 76.68   | 75.93       | 0.841         | 5.531         | 0.054     | 0.423 [0.373–0.473] |
| MRI + Symptom     | 241 (96.40)                      | 0                             | 11 (4.56)                   | 171 (70.95)                | 17.19          | 96.61         | 64.71   | 76.34   | 75.52       | 0.857         | 5.070         | 0.138     | 0.596 [0.518–0.675] |
| MRI + DRE         | 241 (96.40)                      | 0                             | 12 (8.71)                   | 171 (70.95)                | 18.75          | 96.61         | 66.67   | 76.68   | 75.93       | 0.841         | 5.531         | 0.054     | 0.425 [0.347–0.502] |
| MRI + Endoscopy   | 59 (23.60)                       | 0                             | 3 (5.08)                    | 44 (74.58)                 | 21.43          | 97.78         | 75.00   | 80.00   | 79.66       | 0.804         | 9.643         | 0.192     | 0.687 [0.517–0.856] |
| MRI + Endoscopy + Biopsy | 59 (23.60) | 0 or 1 | 6 (10.17) | 31 (52.54) | 46.15 | 83.78 | 50.00 | 81.58 | 74.00 | 0.643 | 2.846 | 0.299 | 0.714 [0.546–0.882] |
| AFP               | 149 (59.60)                      | 0                             | 40 (26.85)                  | 21 (14.09)                 | 95.24          | 19.63         | 31.75   | 91.30   | 40.94       | 0.243         | 1.185         | 0.149     | 0.533 [0.438–0.628] |
| CEA               | 239 (95.60)                      | 0                             | 32 (13.39)                  | 120 (50.21)                | 48.48          | 69.36         | 37.65   | 77.92   | 63.60       | 0.743         | 1.583         | 0.178     | 0.593 [0.511–0.674] |
| CA72.4            | 231 (92.40)                      | 0                             | 51 (22.08)                  | 54 (23.38)                 | 79.69          | 32.34         | 31.10   | 80.60   | 45.45       | 0.628         | 1.178         | 0.120     | 0.538 [0.456–0.620] |
| CA125             | 176 (70.40)                      | 0                             | 32 (18.18)                  | 32 (18.18)                 | 64.00          | 25.40         | 25.40   | 64.00   | 36.36       | 1.418         | 0.858         | -0.106    | 0.545 [0.450–0.639] |
| CA199             | 235 (94.00)                      | 0                             | 18 (7.66)                   | 147 (62.55)                | 27.27          | 86.98         | 45.00   | 75.38   | 70.21       | 0.836         | 2.095         | 0.143     | 0.563 [0.481–0.645] |
| CA242             | 70 (28.00)                       | 0                             | 16 (22.86)                  | 33 (47.14)                 | 76.19          | 56.90         | 39.02   | 86.84   | 62.03       | 0.418         | 1.768         | 0.331     | 0.657 [0.515–0.799] |
| NSE               | 145 (58.00)                      | 0                             | 15 (10.34)                  | 83 (57.24)                 | 37.50          | 79.05         | 40.54   | 76.85   | 67.59       | 0.791         | 1.790         | 0.165     | 0.540 [0.429–0.651] |

Youden Index = Sensitivity + Specificity - 1. The theoretical range of the Youden Index is from -1 to 1, and the practical range in use is often from 0 to 1. Index with negative values were unreasonable and indicated it was unsuitable or even misleading for practice as reassessment tool.
the accuracy was 38.73% and 53.70% respectively, with a p-value of 0.001. Therefore, performing reassessment with a DRE after 95 days could improve its accuracy. For TTE, time to the reassessment of endoscopy, the accuracy before and after the ROC cutoff of 105 days was 73.91% and 42.86% respectively, with a p-value of 0.033. For TTB, time to the reassessment of biopsy, the accuracy before and after ROC cutoff of 100 days was 51.28% and 100% respectively, with a p-value of 0.003, meaning that it was better to perform biopsy after 100 days, as it can improve its accuracy by a large margin. In summary, time to reassessment significantly affected the assessment’s accuracy, with TTR over 100 days obtaining greater accuracy in predicting pCR.

Discussion

In order to establish whether a wait-and-watch strategy is appropriate, there are many tools for or indicators of response reassessment after nCRT in LARC, including common clinical examination, advanced assay, and model prediction. This study aimed to optimize the tools and timing of response reassessment for a wait-and-watch strategy in post-nCRT LARC patients. We found that the combination of endoscopy, biopsy and MRI is an optimal routine reassessment tools combination for a wait-and-watch strategy after nCRT in patients with LARC, while DRE or clinical symptoms outcomes could not be added into any tool’s combination. In addition, in the routine scheme of 12 weeks or longer TTS, we also confirmed that the optimal timing to use these reassessment tools with a higher accuracy was over 100 days after nCRT endpoint. Our results may help practitioners in choosing the optimal reassessment tools and their proper timing for the purpose of establishing a wait-and-watch strategy in patients with LARC.

Common examination consists of inquiry of symptoms, physical examination with a DRE, non-invasive imaging examination with an MRI and a PET-CT, invasive examination with endoscopy and biopsy, and peripheral blood biomarkers tests. Although there were some emerging and cutting-edge techniques for reassessment such as exosomal proteins or ncRNA, biotic ncRNA, blood tests of ctDNA, probe-based confocal laser endomicroscopy (pCLE), and MRI related indicators such as diffusion kurtos imaging (DKI) and intravoxel incoherent motion (IVIM), none of them was that convincing to make them to clinical routine. Moreover, some of the common examinations such as DRE, biopsy, or emerging tools are still in dispute about their ability to independently predict pCR. Therefore, reassessment tools and their combinations are still in development. In 2011, Maas et al. proposed a panel of endoscopy with biopsy and MRI-DWI. In 2013, Habr-Gama et al. proposed a panel of endoscopy, DRE, MRI, TRUS, and PET-CT. In 2015, a nationwide clinical trial in the US employed the Memorial Sloan Kettering Regression Schema (MSKRS) which included a DRE, endoscopy and MRI. In 2017, ESMO clinical practice guidelines mentioned reassessment methods including DRE, endoscopy-biopsy, MRI, TRUS, CEA.
Thus, there is no worldwide consensus on which tools or combinations are optimal for a wait-and-watch strategy use.

In this study, our results showed the low efficiency of clinical examination, including DRE and symptoms evaluation, common laboratory tumor biomarkers, such as CEA and CA199, and their combination with other tools that still could not improve performance, which was in line with previous results [43]. In fact, when it comes to DRE, it had been reported that it should not be used as a sole means of reassessment [41]. However, when part of a combination, it was included in many schemas for reassessment [12, 23, 25]. Nevertheless, our results showed that DRE failed to improve efficacy, or even decreased efficiency, when it was added to any assessment tools combination. Therefore, DRE can be used to determine and help choose between the specific surgical options, however it is not optimal in predicting CR for a wait-and-watch strategy. Moreover, biopsy as an additional reassessment method during an endoscopy procedure had an equivalent efficacy as endoscopy, and their combination could be slightly better but was still quite limited. Finally, MRI combined with endoscopy and biopsy showed the best performance with an accuracy of 74% and AUC of 0.714 (0.546–0.882).

In many developing countries, districts, and primary hospitals, it is difficult to perform advanced assays or new techniques to improve the prediction of CR response to nCRT in patients with LARC. Hence, it is imperative to optimize our current multimodal therapy standardization and schedule. Strict standardization and definition of cCR by reassessment tools of response could be helpful in improving their prediction performance [26]. The ingenious arrangement of multimodal therapy schedule is important as well,
and part of the schedule is the time when the examination or therapy could be performed. In this study, we found that the time interval from nCRT end to the reassessment time point was an important factor in the reassessment efficacy. TTD > 95 days, TTB > 100 days, and TTE < 105 days could obtain a higher accuracy. However, MRI prediction accuracy was insusceptible to the time interval fluctuation. It was intelligible why reassessment tools accuracy could impact time. For post-nCRT LARC patients, time was needed for the tumor residuals to fade away and the scar or nodule was still in the lesion if assessed early on. Thus, untimely reassessments might diminish the accuracy of predicting pCR.

In general, it is recommended and efficient that the time interval from nCRT to reassessment be set after 100 days. To our knowledge, in the scheme of the routine time interval of 12 weeks or longer until surgery, this is the first study to report the importance of timing on reassessment tools use for a wait-and-watch strategy in post-nCRT LARC patients.

| Time to reassessment | Threshold, day | Threshold method | patients in left of threshold (percent of parents, %) | Accuracy in left of threshold (%) | patients in right of threshold (percent of parents, %) | Accuracy in right of threshold (%) | p value |
|----------------------|----------------|-----------------|------------------------------------------------------|----------------------------------|------------------------------------------------------|-----------------------------------|---------|
| TTC, median [IQR], day | 250/250 (100) | 67.50 | ROC cutoff | 63 (25.20) | 52.38 | 187 (74.80) | 60.43 | 0.264 |
| TTD, median [IQR], day | 250/250 (100) | 91.00 | median cutoff | 121 (48.40) | 59.50 | 129 (51.60) | 57.36 | 0.733 |
| TTE, median [IQR], day | 250/250 (100) | 94.50 | ROC cutoff | 142 (56.80) | 38.73 | 108 (43.20) | 53.70 | 0.001 |
| TTB, median [IQR], day | 250/250 (100) | 94.50 | median cutoff | 29 (48.33) | 48.28 | 31 (51.67) | 58.06 | 0.457 |
| TTM, median [IQR], day | 242/250 (96.80) | 55.50 | ROC cutoff | 46 (76.67) | 73.91 | 14 (23.33) | 42.86 | 0.033 |
| 242/250 (96.80) | 56.00 | median cutoff | 25 (50.00) | 52.00 | 25 (50.00) | 72.00 | 0.153 |

TTC time to clinical examination; TTD time to digital rectal examination; TTE time to endoscopy; TTB time to biopsy; TTM time to MRI
Fig. 4 True or false prediction in different timing of response reassessment tools. The patients were divided into two groups including true and false prediction group by tools response reassessment outcomes. The two groups’ distribution in time interval to reassessment were shown separately, but there was no difference in two group as time analysis as a whole. The correlation of prediction of CR with the time to reassessment of (A) MRI, (B) Endoscopy, (C) Examination of symptom, (D) Biopsy, (E) DRE. The value “1” and “2” were the groups’ categorical variables. The value of “1” indicated “False Prediction” and “2” indicated “True Prediction.” The difference of distribution would show as timing longer than 100 days in biopsy. There was no any distribution difference in any timepoint in the reassessment of MRI, DRE and examination of symptom. The $p$ value in detail was shown in Table 4. Abbreviation: CR: complete response; DRE: digital rectal examination
in the CR group. However, the wait-and-watch patients with 2-year sustained cCR were often considered pCR analogue in practice and literature [21] because recurrence-free patients in the first 2 years had very low recurrence probability (3.85%) after 2 years [11].

In conclusion, it was confirmed that the response reassessment by endoscopy and biopsy for post-nCRT LARC patients obtained a higher efficacy compared to MRI, DRE, clinical symptoms and peripheral blood common tumor markers. DRE and symptoms assessment, as one indicator of the panel, still failed to improve the efficacy of predicting pCR, and thus perhaps should not be used as part of reassessment method combinations anymore. Although MRI also failed to improve the AUC when added into the combination of endoscopy and biopsy, the accuracy had increased. Therefore, at present, the combination of endoscopy, biopsy and MRI is recommended as the suitable reassessment combination if the medical condition was limited. In addition, the time interval from nCRT endpoint to reassessment has a significant influence on the predictive accuracy. Performing response reassessment with endoscopy and biopsy 100 days after nCRT could obtain higher accuracy. As for the MRI, more flexibility regarding the time of using it can be implemented.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00384-022-04268-7.

Author contribution All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Junbing Chen, Zhourqiao Wu and Xiaoyan Zhang. The first draft of the manuscript was written by Junbing Chen and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Funding information his study was funded by the National Key Technology Research and Development Program of the Ministry of Science and Technology of China (D171100006517004), the Young Scholar Program of Beijing Hospitals Authority (QMS20191103), Clinical Medicine Plus X—Young Scholars Project of Peking University (PKU2022LCXQ038), the Fundamental Research Funds for the Central Universities and the Science Foundation of Peking University Cancer Hospital (KC2210).

Declarations

Ethics approval Ethics approval was granted by the Peking University Cancer Hospital Ethics Committee.

Conflict of interest The authors declare no competing interests.

References

1. Dekker E, Tanis PJ, Vleugels JLA, Kasi PM, Wallace MB (2019) Colorectal cancer. Lancet 394(10207):1467–1480. https://doi.org/10.1016/S0140-6736(19)32319-0

2. Jimenez-Fonseca P, Salazar R, Valenti V, Msaouel P, Carmona-Bayonas A (2022) Is short-course radiotherapy and total neoadjuvant therapy the new standard of care in locally advanced rectal cancer? A sensitivity analysis of the RAPIDO clinical trial. Ann Oncol 33(8):786–793. https://doi.org/10.1016/j.annonc.2022.04.010

3. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fiettkau R, Martus P, Tschmädtl J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study G (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17):1731–1740. https://doi.org/10.1056/NEJMoa040694

4. Jin J, Tang Y, Hu C, Jiang LM, Jiang J, Li N, Liu WY, Chen SL, Li S, Lu NN, Cai Y, Li YH, Zhu Y, Cheng GH, Zhang HY, Wang X, Zhu SY, Wang J, Li GF, Yang JL, Zhang K, Chi Y, Yang L, Zhou HT, Zhou AP, Zou SM, Fang H, Wang SL, Zhang HZ, Wang XS, Wei LC, Wang WL, Liu SX, Gao YH, Li YX (2022) Multicenter, randomized, phase iii trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol 40(15):1681–1692. https://doi.org/10.1200/JCO.21.01667

5. Janjan NA, Khoo VS, Abbruzzese J, Pazdur R, Dubrow R, Cleary KR, Allen PK, Lynch PM, Glober G, Wolff R, Rich TA, Skibber J (1999) Tumor downstaging and sphincter preservation with preoperative chemoradiotherapy in locally advanced rectal cancer: the M. D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 44(5):1027–1038. https://doi.org/10.1016/s0360-3016(99)00099-1

6. Maas M, Nelemans PJ, Valentini V, Das P, Rodel C, Kuo LJ, Calvo FA, Garcia-Aguilar J, Glynne-Jones R, Haustermans K, Mohiuddin M, Pucciarelli S, Small W Jr, Suarez J, Theodoropoulos G, Biondo S, Beets-Tan RG, Beets GL (2010) Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol 11(9):835–844. https://doi.org/10.1016/s1470-4247(10)70172-8

7. Al-Sukhni E, Attwood K, Mattson DM, Gabriel E, Nurkin SJ (2016) Predictors of Pathologic Complete Response Following Neoadjuvant Chemoradiotherapy for Rectal Cancer. Ann Surg Oncol 23(4):1177–1186. https://doi.org/10.1245/s10434-015-5017-y

8. Paun BC, Cassie S, MacLean AR, Dixon E, Buie WD (2010) Postoperative complications following surgery for rectal cancer. Ann Surg 251(5):807–818. https://doi.org/10.1097/SLA.0b013e3181ad96d

9. Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro U Jr, Silva e Sousa AH Jr., Campos FG, Kiss DR, Gama-Rodrigues J (2004) Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 240 (4):711–717 discussion 717–718. https://doi.org/10.1097/01.sla.0000141194.27992.32

10. Maas M, Beets-Tan RG, Lamberts DM, Lammering G, Nelemans PJ, Engelen SM, van Dam RM, Jansen RL, Sosef M, Leijtens JW, Hulselwe KW, Buijsen J, Beets GL (2011) Wait-and-see policy for clinical complete responders after neoadjuvant treatment for rectal cancer following chemoradiation therapy: long-term results. Ann Surg 251(5):807–818. https://doi.org/10.1097/SLA.0b013e3181ad96d

11. van der Valk MJM, Hilling DE, Bastiaannet E, Meershoeck-Klein Kranenburg E, Beets GL, Figueiredo NL, Habr-Gama A, Perez RO, Renehan AG, van de Velde CJH, Consortium I (2018) Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 391(10139):2537–2545. https://doi.org/10.1016/S0140-6736(18)31078-X

12. Maas M, Lamberts DM, Nelemans PJ, Heijnen LA, Martens MH, Leijtens JW, Sosef M, Hulselwe KW, Hoof C, Breukink SO, Stassen
13. Svoboda M, Sana J, Fabian P, Kocakova I, Gombovska J, Nekvindova J, Radova L, Vyzula R, Slaby O (2012) MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat Oncol 7:195. https://doi.org/10.1186/1748-717X-7-195

14. Kuan FC, Lai CH, Ku HY, Wu CF, Hsieh MC, Liu TW, Yeh CY, Lee KD (2017) The survival impact of delayed surgery and adjuvant chemotherapy on stage II/III rectal cancer with pathological complete response after neoadjuvant chemoradiation. Int J Cancer 140(7):1662–1669. https://doi.org/10.1002/ijc.30562

15. Mei S-W, Liu Z, Wei F-Z, Chen J-N, Wang Z-J, Shen H-Y, Li J, Zhao F-Q, Pei W, Wang Z, Wang X-S, Liu Q (2020) Impact of interval between neoadjuvant chemoradiotherapy and surgery in rectal cancer patients. World J Gastroenterol 26(31):4624–4638. https://doi.org/10.3748/wjg.v26.i31.4624

16. Wang X, Zheng Z, Zhu H, Yu Q, Huang S, Lu X, Huang Y, Chi P (2021) Timing to achieve the best recurrence-free survival after neoadjuvant chemoradiotherapy in locally advanced rectal cancer: experience in a large-volume center in China. Int J Colorectal Dis 36(5):1007–1016. https://doi.org/10.1007/s00384-020-03829-y

17. Wang X-B, Zhang Q, Chen M, Liu Y, Zheng J, Lan P, He F (2020) Prognostic Value of Interval Between the Initiation of Neoadjuvant Treatment to Surgery for Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemotherapy, Radiotherapy and Definitive Surgery. Front Oncol 10:1280. https://doi.org/10.3389/fonc.2020.01280

18. Liu Z, Zhang XY, Shi YJ, Wang L, Zhu HT, Tang Z, Wang S, Li XT, Tian J, Sun YS (2017) Radiomics Analysis for Evaluation of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. Clin Cancer Res 23(23):7253–7262. https://doi.org/10.1158/1078-0432.CCR-17-1038

19. Wang L, Li ZY, Li ZW, Li YH, Sun YS, Ji JF, Gu J, Cai Y (2015) Efficacy and safety of neoadjuvant intensity-modulated radiotherapy with concurrent capcitabine for locally advanced rectal cancer. Dis Colon Rectum 58(2):186–192. https://doi.org/10.1097/DCR.0000000000000294

20. Wu AW, Cai Y, Li YH, Wang L, Li ZW, Sun YS, Ji JF (2018) Pattern and Management of Recurrence of Mid-Low Recal Cancer After Neoadjuvant Intensity-Modulated Radiotherapy: Single-Center Results of 687 Cases. Clin Colorectal Cancer 17(2):e307–e313. https://doi.org/10.1016/j.clcc.2018.01.006

21. Nahas SC, Rizkallah Nahas CS, Sarpavan Marques CF, Ribeiro U, Cotti GC, Imperiale AR, Capareli FC, Chih Chen AT, Hoff PM, Crocchello I (2016) Pathologic Complete Response in Rectal Cancer: Can We Detect It? Lessons Learned From a Proposed Randomized Trial of Watch-and-Wait Treatment of Rectal Cancer. Dis Colon Rectum 59(4):255–263. https://doi.org/10.1097/DCR.0000000000001558

22. D’Souza N, de Nerec Tot Babberich MPM, d’Hoore A, Tiret E, Xynos E, Beets-Tan RGH, Nagtegaal ID, Blomqvist L, Holm T, Grimelius L, Bacy A, Cervantes A, Glyne-Jones R, West NP, Perez RO, Quadros C, Lee KY, Madiba TE, Wexner SD, Garcia-Aguilar J, Sahani D, Moran B, Tekkis P, Rutten HJ, Tanis PJ, Wiggers T, Brown G (2019) Definition of the Rectum: An International Expert-based Delphi Consensus Ann Surg 270(6):955–959. https://doi.org/10.1097/SLA.S0000000000003251

23. Habr-Gama A, Sabagga J, Gama-Rodrigues J, Sao Juliao GP, Proscuroshim I, Balaio Aguilar P, Nadalin W, Perez RO (2013) Watch and wait approach following extended neoadjuvant chemoradiation for distal rectal cancer: are we getting closer to anal cancer management? Dis Colon Rectum 56(10):1109–1117. https://doi.org/10.1097/DCR.0b013e31822a5e4e

24. Smith JJ, Chow OS, Gollub MJ, Nash GM, Templek L, Weiser MR, Guillen JG, Paty PB, Avila K, Garcia-Aguilar J, Rectal Cancer C (2015) Organ Preservation in Rectal Adenocarcinoma: a Phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer 15:767. https://doi.org/10.1186/s12885-015-1632-z

25. Glyne-Jones R, Wyrwicz L, Tiret E, Brown G, Rodel C, Cervantes A, Arnold D, Committee EG (2017) Rectal cancer: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28 (suppl_4):iv22-iv40. https://doi.org/10.1093/annonc/mdx224

26. Habr-Gama A, Perez RO, Wynn G, Marks J, Kessler H, Gama-Rodrigues J (2010) Complete clinical response after neoadjuvant chemoradiation therapy for distal rectal cancer: characterization of clinical and endoscopic findings for standardization. Dis Colon Rectum 53(12):1692–1698. https://doi.org/10.1097/DCR.0b013e3181f4b889

27. Song M, Li S, Wang H, Hu K, Wang F, Teng H, Wang Z, Liu J, Jia AY, Cai Y, Li Y, Zhu X, Geng J, Zhang Y, Wan X, Wang W (2022) MRI radiomics independent of clinical baseline characteristics and neoadjuvant treatment modalities predicts response to neoadjuvant therapy in rectal cancer. Br J Cancer. https://doi.org/10.1038/s41416-022-01786-7

28. Perez RO, Habr-Gama A, Sao Juliao GP, Lynn PB, Sabbagh C, Proscuroshim I, Campos FG, Gama-Rodrigues J, Nahas SC, Buchpiguel CA (2014) Predicting complete response to neoadjuvant CRT for distal rectal cancer using sequential PET/CT imaging. Tech Coloproctol 18(8):699–708. https://doi.org/10.1007/s10151-013-1119-9

29. Ogura A, Chino A, Konishi T, Akiyoshi T, Kishihara T, Tamegai Y, Ueno M, Igarashi M (2015) Endoscopic evaluation of clinical response after preoperative chemoradiotherapy for lower rectal cancer: the significance of endoscopic complete response. Int J Colorectal Dis 30(3):367–373. https://doi.org/10.1007/s00384-014-2105-6

30. Wallin U, Rothenberger D, Lowry A, Luepker R, Mellgren A (2013) CEAC - a predictor for pathologic complete response after neoadjuvant therapy for rectal cancer. Dis Colon Rectum 56(7):859–868. https://doi.org/10.1097/DCR.0b013e31822a5e4e

31. Probst CP, Becerra AZ, Aquina CT, Tejani MA, Hensley BJ, Gonzalez MG, Noyes K, Monson JRT, Fleming FJ (2016) Watch and Wait?--Elevated pretreatment CEA is associated with decreased pathological complete response in rectal cancer. J Gastrointest Surg 20 (1). https://doi.org/10.1007/s11605-015-2987-9

32. Yang KL, Yang SH, Liang WY, Kuo YJ, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC, Chu LS, Wang LW (2013) Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. Radiat Oncol 8:43. https://doi.org/10.1186/1748-717X-8-43

33. Stryleb U, Marczak L, Zeman M, Polanski K, Mielanczyk Ł, Klymenko O, Samekal-Czajka A, Jackowiak P, Smolarz M, Chekan M, Zembala-Nożyńska E, Wiślik P, Pietrowska M, Wojakowska A (2022) Molecular composition of serum exosomes could discriminate rectal cancer patients with different responses to neoadjuvant radiotherapy. Cancers 14 (4). https://doi.org/10.3390/cancers14040993

34. Baek DW, Kim G, Kang BW, Kim HJ, Park SY, Park JS, Choi G-S, Kang MK, Hur K, Kim JG (2020) High expression of microRNA-199a-5p is associated with superior clinical outcomes in patients
with locally advanced rectal cancer. J Cancer Res Clin Oncol 146(1):105–115. https://doi.org/10.1007/s00432-019-03099-4
35. Lopes-Ramos CM, Hahr-Gama A, Quevedo BD, Felício NM, Bettoni F, Koyama FC, Asprino PF, Galante PA, Gama-Rodrigues J, Camargo AA, Perez RO, Parmigiani RB (2014) Overexpression of miR-21-5p as a predictive marker for complete tumor regression to neoadjuvant chemoradiotherapy in rectal cancer patients. BMC Med Genomics 7:68. https://doi.org/10.1186/s12920-014-0068-7
36. Murrahashi S, Akiyoshi T, Sano T, Fukunaga Y, Noda T, Ueno M, Zembutsu H (2020) Serial circulating tumour DNA analysis for locally advanced rectal cancer treated with preoperative therapy: prediction of pathological response and postoperative recurrence. Br J Cancer 123(5):803–810. https://doi.org/10.1038/s41416-020-0941-4
37. McDuff SGR, Hardiman KM, Ulintz PJ, Parikh AR, Zheng H, Kim DW, Lennerz JK, Hazar-Rethinam M, Van Seventer EE, Fetter JJ, Nadres B, Eyler CE, Ryan DP, Weekes CD, Clark JW, Cusack JC, Goyal L, Zhu AX, Wo JY, Bíaszkowsky LS, Allen J, Corcoran RB, Hong TS (2021) Circulating Tumor DNA Predicts Pathologic and Clinical Outcomes Following Neoadjuvant Chemoradiation and Surgery for Patients With Locally Advanced Rectal Cancer. JCO Precis Oncol. https://doi.org/10.1200/PO.20.00220
38. Zhou J, Wang C, Lin G, Xiao Y, Jia W, Xiao G, Liu Q, Wu B, Wu A, Qu H, Zhang F, Hu K, Xue H, Shen Z, Wang Z, Han J, Niu B, Xu Y, Yu Z, Yang L (2021) Serial Circulating Tumor DNA in Predicting and Monitoring the Effect of Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer: A Prospective Multicenter Study, Clin Cancer Res 27(1):301–310. https://doi.org/10.1158/1078-0432.CCR-20-2299
39. Safatle-Ribeiro AV, Marques CFS, Pires C, Arraes L, Baba ER, Meirelles L, Kagawuti FS, da Costa MB, Lenz LT, de Lima MS, Gusmon-Oliveira CC, Ribeiro U Jr, Maluf-Filho F, Nahas SC (2021) Diagnosis of Clinical Complete Response by Probe-Based Confocal Laser Endomicroscopy (pCLE) After Chemoradiation for Advanced Rectal Cancer. J Gastrointest Surg 25(2):357–368. https://doi.org/10.1007/s11605-020-04878-y
40. Yang L, Xia C, Zhao J, Zhou X, Wu B (2021) The value of intra-voxel incoherent motion and diffusion kurtosis imaging in the assessment of tumor regression grade and T stages after neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer. Eur J Radiol 136:109504. https://doi.org/10.1016/j.ejrad.2020.109504
41. Guillem JG, Chessin DB, Shia J, Moore HG, Mazumdar M, Bernard B, Paty PB, Saltz L, Minsky BD, Weiser MR, Temple LKF, Cohen AM, Wong WD (2005) Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate end point. J Clin Oncol: Official J Am Soc Clin Oncol 23(15):3475–3479
42. Perez RO, Hahr-Gama A, Pereira GV, Lynn PB, Alves PA, Proscuresthem I, Rawet V, Gama-Rodrigues J (2012) Role of biopsies in patients with residual rectal cancer following neoadjuvant chemoradiation after downsizing: can they rule out persisting cancer? Colorectal Dis 14(6):714–720. https://doi.org/10.1111/j.1463-1318.2011.02761.x
43. Hiotis SP, Weber SM, Cohen AM, Minsky BD, Paty PB, Guillem JG, Wagman R, Saltz LB, Wong WD (2002) Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: an analysis of 488 patients. J Am Coll Surg 194(2):131–135 discussion 135–136. https://doi.org/10.1016/s1072-7515(01)01159-0
44. Smith FM, Chang KH, Sheahan K, Hyland J, O’Connell PR, Winter DC (2012) The surgical significance of residual mucosal abnormalities in rectal cancer following neoadjuvant chemoradiotherapy. Br J Surg 99(7):993–1001. https://doi.org/10.1002/bjs.8700
45. Chinese W, Wait Database Research Cooperation G, Chinese Association of Surgeons CSOCCMDA, Chinese Society of Colorectal Surgery CMA, Colorectal Cancer Physician Specialty Committee CMDA, Radiation Therapy Specialty Committee CAA (2020) Consensus on the watch and wait policy in rectal cancer patients after neoadjuvant treatment (2020 version). Zhonghua Wei Chang Wai Ke Za Zhi 23(1):1–9. https://doi.org/10.3760/cma.j.issn.1671-0274.2020.01.001

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.